Their application may be more suitable to treating systemic inflammation (e.g., sepsis) or diseases in which NF-κB inhibition is more clearly linked only to proinflammatory processes (e.g., COVID-19, RA). This evidence concerns the gene NFKB1 and rheumatoid arthritis.